Document is current
Any future updates will be listed below
-
Authors
Leventhal, Shanna S.
Bisom, Thomas
Clift, Dean https://orcid.org/0000-0001-8141-7817
Rao, Deepashri
Meade-White, Kimberly
Shaia, Carl https://orcid.org/0000-0001-8907-8821
Murray, Justin
Mihalakakos, Evan A.
Hinkley, Troy https://orcid.org/0000-0003-4833-0255
Reynolds, Steven J.
Best, Sonja M. https://orcid.org/0000-0003-0206-297X
Erasmus, Jesse H. https://orcid.org/0000-0003-1612-2697
James, Leo C. https://orcid.org/0000-0003-2131-0334
Feldmann, Heinz https://orcid.org/0000-0001-9448-8227
Hawman, David W. https://orcid.org/0000-0001-8233-8176
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (N/A)
- License Information
-
More Information
Article History
Received: 6 February 2024
Accepted: 9 October 2024
First Online: 25 October 2024
Competing interests
: J.E. has equity interest in HDT Bio and is co-inventor on U.S. patent application no. 62/993,307 “Compositions and methods for delivery of RNA” pertaining to formulations for RNA delivery. DWH, JE and HF are inventors on U.S. patent application number 63/365,015 “Replicating RNA vaccine for Crimean-Congo hemorrhagic fever virus” regarding the repRNA for use against CCHFV. The remaining authors declare no competing interests.
